RAS and ROS in rhabdomyosarcoma.

Journal Article (Journal Article)

The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.

Full Text

Duke Authors

Cited Authors

  • Zhang, M; Linardic, CM; Kirsch, DG

Published Date

  • December 9, 2013

Published In

Volume / Issue

  • 24 / 6

Start / End Page

  • 689 - 691

PubMed ID

  • 24332036

Pubmed Central ID

  • 24332036

Electronic International Standard Serial Number (EISSN)

  • 1878-3686

Digital Object Identifier (DOI)

  • 10.1016/j.ccr.2013.11.015


  • eng

Conference Location

  • United States